155 related articles for article (PubMed ID: 31663481)
1. The Increase of HIV-1 Infection, Neurocognitive Impairment, and Type 2 Diabetes in The Rio Grande Valley.
De La Garza R; Rodrigo H; Fernandez F; Roy U
Curr HIV Res; 2019; 17(6):377-387. PubMed ID: 31663481
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral therapy modifies the genetic effect of known type 2 diabetes-associated risk variants in HIV-infected women.
Frasco MA; Karim R; Van Den Berg D; Watanabe RM; Anastos K; Cohen M; Gange SJ; Gustafson DR; Liu C; Tien PC; Mack WJ; Pearce CL
AIDS; 2014 Jul; 28(12):1815-23. PubMed ID: 24932614
[TBL] [Abstract][Full Text] [Related]
3. Association of HIV-1 Infection and Antiretroviral Therapy With Type 2 Diabetes in the Hispanic Population of the Rio Grande Valley, Texas, USA.
Lopez-Alvarenga JC; Martinez DA; Diaz-Badillo A; Morales LD; Arya R; Jenkinson CP; Curran JE; Lehman DM; Blangero J; Duggirala R; Mummidi S; Martinez RD
Front Med (Lausanne); 2021; 8():676979. PubMed ID: 34291061
[TBL] [Abstract][Full Text] [Related]
4. Associations of antiretroviral therapy and comorbidities with neurocognitive outcomes in HIV-1-infected patients.
Siangphoe U; Archer KJ; Nguyen C; Lee KR
AIDS; 2020 May; 34(6):893-902. PubMed ID: 32028325
[TBL] [Abstract][Full Text] [Related]
5. Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection.
Evering TH; Applebaum A; La Mar M; Garmon D; Dorfman D; Markowitz M
AIDS; 2016 Jan; 30(2):203-10. PubMed ID: 26684817
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Syndrome Among People Living with HIV Receiving Medical Care in Southern United States: Prevalence and Risk Factors.
Sears S; Buendia JR; Odem S; Qobadi M; Wortley P; Mgbere O; Sanders J; Spencer EC; Barnes A
AIDS Behav; 2019 Nov; 23(11):2916-2925. PubMed ID: 30929149
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and 1-year incidence of HIV-associated neurocognitive disorder (HAND) in adults aged ≥50 years attending standard HIV clinical care in Kilimanjaro, Tanzania.
Flatt A; Gentry T; Kellett-Wright J; Eaton P; Joseph M; Urasa S; Howlett W; Dekker M; Kisoli A; Rogathe J; Henderson L; Lewis T; Thornton J; McCartney J; Yarwood V; Irwin C; Mukaetova-Ladinska EB; Akinyemi R; Gray WK; Walker RW; Dotchin CL; Quaker AS; Makupa PC; Paddick SM
Int Psychogeriatr; 2023 Jul; 35(7):339-350. PubMed ID: 33757616
[TBL] [Abstract][Full Text] [Related]
8. HIV-Associated Neurocognitive Disorders: The First Longitudinal Follow-Up of a cART-Treated Cohort of Older People in Sub-Saharan Africa.
Spooner R; Ranasinghe S; Urasa S; Yoseph M; Koipapi S; Mukaetova-Ladinska EB; Lewis T; Howlett W; Dekker M; Kisoli A; Gray WK; Walker RW; Dotchin CL; Kalaria R; Lwezuala B; Makupa PC; Akinyemi R; Paddick SM
J Acquir Immune Defic Syndr; 2022 Jun; 90(2):214-222. PubMed ID: 35125473
[TBL] [Abstract][Full Text] [Related]
9. Cognitive screening in treatment-naïve HIV-infected individuals in Hong Kong - a single center study.
Chan FCC; Chan P; Chan I; Chan A; Tang THC; Lam W; Fong WC; Lee MP; Li P; Chan GHF
BMC Infect Dis; 2019 Feb; 19(1):156. PubMed ID: 30760220
[TBL] [Abstract][Full Text] [Related]
10. Changing Trends in Complications and Mortality Rates Among US Youth and Young Adults With HIV Infection in the Era of Combination Antiretroviral Therapy.
Mirani G; Williams PL; Chernoff M; Abzug MJ; Levin MJ; Seage GR; Oleske JM; Purswani MU; Hazra R; Traite S; Zimmer B; Van Dyke RB;
Clin Infect Dis; 2015 Dec; 61(12):1850-61. PubMed ID: 26270680
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D deficiency is associated with neurocognitive impairment in HIV-infected subjects.
Vergori A; Pinnetti C; Lorenzini P; Brita A; Libertone R; Mastrorosa I; Cicalini S; Antinori A; Ammassari A
Infection; 2019 Dec; 47(6):929-935. PubMed ID: 31183805
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in HIV-associated neurocognitive disorders: a focus on older adults and sub-Saharan Africa.
Paddick SM; Mukaetova-Ladinska EB
Curr Opin Psychiatry; 2024 Mar; 37(2):87-93. PubMed ID: 38226543
[TBL] [Abstract][Full Text] [Related]
13. Screening for HIV-Associated Neurocognitive Disorders: Sensitivity and Specificity.
Robbins RN; Scott TM; Gouse H; Marcotte TD; Rourke SB
Curr Top Behav Neurosci; 2021; 50():429-478. PubMed ID: 32677005
[TBL] [Abstract][Full Text] [Related]
14. Potential pharmacological approaches for the treatment of HIV-1 associated neurocognitive disorders.
Omeragic A; Kayode O; Hoque MT; Bendayan R
Fluids Barriers CNS; 2020 Jul; 17(1):42. PubMed ID: 32650790
[TBL] [Abstract][Full Text] [Related]
15. Comorbid depression and apathy in HIV-associated neurocognitive disorders in the era of chronic HIV infection.
Cysique LA; Brew BJ
Handb Clin Neurol; 2019; 165():71-82. PubMed ID: 31727231
[TBL] [Abstract][Full Text] [Related]
16. The Longitudinal Effects of Blood Pressure and Hypertension on Neurocognitive Performance in People Living With HIV.
Guzman VA; Cham H; Gutierrez J; Byrd D; Morris EP; Tureson K; Morgello S; Mindt MR;
J Acquir Immune Defic Syndr; 2021 Oct; 88(2):197-205. PubMed ID: 34081663
[TBL] [Abstract][Full Text] [Related]
17. HIV-Associated Neurocognitive Disorders--An issue of Growing Importance.
Chan LG; Wong CS
Ann Acad Med Singap; 2013 Oct; 42(10):527-34. PubMed ID: 24254240
[TBL] [Abstract][Full Text] [Related]
18. HIV cure research: advances and prospects.
Passaes CP; Sáez-Cirión A
Virology; 2014 Apr; 454-455():340-52. PubMed ID: 24636252
[TBL] [Abstract][Full Text] [Related]
19. Association of HIV-infection, antiretroviral treatment and metabolic syndrome with large artery stiffness: a cross-sectional study.
Msoka TF; Van Guilder GP; Smulders YM; van Furth M; Bartlett JA; van Agtmael MA
BMC Infect Dis; 2018 Dec; 18(1):708. PubMed ID: 30594160
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus and atherosclerosis.
Farrugia PM; Lucariello R; Coppola JT
Cardiol Rev; 2009; 17(5):211-5. PubMed ID: 19690471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
